<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241930</url>
  </required_header>
  <id_info>
    <org_study_id>H97HA03792</org_study_id>
    <secondary_id>1 H97HA03792-01-00</secondary_id>
    <nct_id>NCT00241930</nct_id>
  </id_info>
  <brief_title>Integrating Buprenorphine Into HIV Treatment</brief_title>
  <official_title>SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organization to Achieve Solutions in Substance Abuse (OASIS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organization to Achieve Solutions in Substance Abuse (OASIS)</source>
  <brief_summary>
    <textblock>
      We hypothesize that integrating drug treatment into HIV treatment will improve HIV outcomes&#xD;
      as well as drug treatment outcomes in heroin users. This study will test this hypothesis by&#xD;
      randomizing patients to two groups. The first group will receive HIV treatment and&#xD;
      buprenorphine treatment contemporaneously at their HIV clinic. The second group will receive&#xD;
      HIV treatment at their HIV clinic, and go to another facility to receive buprenorphine&#xD;
      treatment services.&#xD;
&#xD;
      We will look at HIV outcomes such as CD4 counts, HIV viral loads, and attendance at&#xD;
      appointments and drug treatment outcomes such as receipt of buprenorphine and urine&#xD;
      toxicology testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that integrating buprenorphine within the context of&#xD;
      primary care HIV treatment will improve outcomes for HIV-infected heroin users vs providing&#xD;
      buprenorphine services at a separate, off-site facility. As a means of engagement, we will&#xD;
      offer the OASIS education group each week at each facility. For those randomized to&#xD;
      integrated care, subjects will attend one education session weekly at the time of their HIV&#xD;
      clinic. During these sessions, subjects will receive contemporaneous HIV clinic appointments&#xD;
      (monthly), case management (monthly), drug counseling (twice monthly), and buprenorphine&#xD;
      (which will be dispensed weekly.) For those randomized to separate care, subjects will attend&#xD;
      HIV clinic appointments monthly, and will attend weekly education sessions at the OASIS&#xD;
      facility. During these sessions, subjects will receive weekly buprenorphine, twice monthly&#xD;
      drug counseling, and monthly case management.&#xD;
&#xD;
      We will measure outcomes by reporting attendance, CD4 counts, HIV viral loads, urine&#xD;
      toxicology testing on at least a quarterly basis. We will also measure patient satisfaction,&#xD;
      knowledge, quality of life, and a number of other outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>February 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Impact of integrated care vs nonintegrated care on:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>a. Substance use and high-risk transmission behaviors</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>b. Medical engagement and outcomes</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>c. Psychosocial indices, such as criminal justice, employment, housing, and education</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Acceptability of HIV treatment-based buprenorphine therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Health services utilization</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Opiate Dependence</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Integrating drug treatment into HIV services</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV+ as verified by lab report&#xD;
&#xD;
          -  DSM-IV diagnosis of opioid dependence&#xD;
&#xD;
          -  Speaks/understands English&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LFT's (transaminase) &gt;5x ULN&#xD;
&#xD;
          -  DSV-IV criteria for benzodiazepine abuse or dependence within the last month&#xD;
&#xD;
          -  DSM-IV criteria for alcohol dependence within the past 6 months&#xD;
&#xD;
          -  Actively suicidal&#xD;
&#xD;
          -  Methadone dose exceeds level allowing safe transition to buprenorphine&#xD;
&#xD;
          -  Pregnant women and women trying to become pregnant&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Clinical judgement that patient is inappropriate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana L Sylvestre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Organization to Achieve Solutions in Substance Abuse (OASIS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Finkelstein, ScD</last_name>
    <role>Study Director</role>
    <affiliation>New York Academy of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana L Sylvestre, MD</last_name>
    <phone>510-834-5442</phone>
    <email>dsylves@itsa.ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laphyne Barrett</last_name>
    <phone>510-834-5442</phone>
    <email>oasisclinic@sbcglobal.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alameda County Medical Center HIV Clinic</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Smith</last_name>
      <phone>510-437-4888</phone>
    </contact>
    <contact_backup>
      <last_name>Silver Sisneros, MD</last_name>
      <phone>510-437-4891</phone>
      <email>ssisneros@acmedctr.org</email>
    </contact_backup>
    <investigator>
      <last_name>Silver Sisneros, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OASIS</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laphyne Barrett</last_name>
      <phone>510-834-5442</phone>
      <email>oasisclinic@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>Diana L Sylvestre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairmont Hospital HIV Clinic</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Smith</last_name>
      <phone>510-437-4888</phone>
    </contact>
    <contact_backup>
      <last_name>Beth Schweitzer, MD</last_name>
      <phone>510-667-3201</phone>
    </contact_backup>
    <investigator>
      <last_name>Beth Schweitzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>October 24, 2005</last_update_submitted>
  <last_update_submitted_qc>October 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2005</last_update_posted>
  <keyword>Heroin</keyword>
  <keyword>HIV</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>integration</keyword>
  <keyword>drug treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

